Insider Selling: Billiontoone (NASDAQ:BLLN) CTO Sells $928,600.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of Billiontoone stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $92.86, for a total transaction of $928,600.00. Following the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $92,860. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total transaction of $2,045,400.00.

Billiontoone Price Performance

Billiontoone stock opened at $93.33 on Friday. The firm has a fifty day moving average of $116.41 and a 200-day moving average of $94.59. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.40 billion and a P/E ratio of 133.33.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million for the quarter. As a group, analysts predict that Billiontoone, Inc. will post 0.83 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on BLLN. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. BTIG Research lowered their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. JPMorgan Chase & Co. reduced their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Finally, Guggenheim began coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $126.71.

Hedge Funds Weigh In On Billiontoone

Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in shares of Billiontoone by 151.8% during the first quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock valued at $2,408,000 after acquiring an additional 18,389 shares in the last quarter. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% during the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after acquiring an additional 148,446 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Billiontoone in the first quarter worth about $1,058,000. Baillie Gifford & Co. acquired a new position in shares of Billiontoone in the fourth quarter worth about $103,786,000. Finally, Emerald Mutual Fund Advisers Trust boosted its holdings in Billiontoone by 11.9% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after purchasing an additional 14,072 shares during the last quarter.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.